REFERENCES
- Foley K M. Advances in cancer pain management in 2005. Gynecol Oncol. 2005; 99: S126
- Katz N P, Adams E H, Benneyan J C, et al. Foundations of opioid risk management. Clin J Pain 2007; 23: 103–118
- NID A InfoFacts. Prescription Pain and Other Medications, Available at: http://www.nida.nih.gov/infofacts/PainMed.html Accessed April 20, 2007
- Kreek M J. Methadone-related opioid agonist pharmacotherapy for heroin addiction: history, recent molecular and neurochemical research and future in mainstream medicine. Ann NY Acad Sci. 2000; 909: 186–216
- Bart G, Kreek M J, Ott J, et al. Increased attributable risk related to a functional muopioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology 2005; 30: 417–422
- Nishizawa D, Han W, Hasegawa J, et al. Association of microopioid receptor gene polymorphism A118G with alcohol dependence in a Japanese population. Neuropsychobiology 2006; 53: 137–141
- Keith D E, Murray S R, Zaki P A, et al. Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem. 1996; 271: 19021–19024
- Hashimoto T, Saito Y, Yamada K, et al. En-hancement of morphine analgesic effect with induction of muopioid receptor endocytosis in rats. Anesthesiol-ogy 2006; 105: 574–580
- Seltzer Z, Dorfman R. Identifying genetic and environmental risk factors for chronic orofacial pain syndromes: human models. J Orofac Pain 2004; 18: 311–317
- Tegeder I, Costigan M, Griffin R S, et al. GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nat Med. 2006; 12: 1269–1277
- Reyes-Gibby C, Shete S, Rakvag T, et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 2006, Dec 5; [Epub ahead of print]
- Friedman R., Li V, Mehrotra D. Treating pain patients at risk: evaluation of a screening tool in opioid-treated pain patients with and without addiction. Pain Med. 2003; 4: 182–185
- Passik S, Kirsh K, Whitcomb L, Portenoy R K, Katz N P, Kleinman L, Dodd S L, Schein J R. A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy. Clin Ther. 2004; 26: 552–561
- Daniels D, Lenard N, Etienne C, et al. Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. PNAS. 2005; 102: 19208–19213
- Boyd C, McCabe S, Cranford J, et al. Prescription drug abuse and diversion among adolescents in a southeast Michigan school district. Arch Pediatr Adolesc Med. 2007; 161: 276–281
- Teter C, McCabe S, LaGrange K, et al. Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy 2006; 26: 1501–1510
- Gureje O, Von Korff M, Simon G E, Gâter R. Persistent pain and well being: a World Health Organization Study in Primary Care. JAMA 1998; 280: 147–151
- Sullivan M, Edlund M, Zhang L, et al. Association between mental health disorders, problem drug use, and regular prescription opioid use. Arch Intern Med. 2006; 166: 2087–2093
- Fudala P A, Johnson R D. Development of opioid formulations with limited diversion and abuse potential. Drug Alcohol Depend. 2006; 83: S40–S47
- deCharms R, Maeda A, Glover G, et al. Control over brain activation and pain learned by using real-time functional MRI. PNAS. 2005; 102: 18626–18631